



1641

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Masanobu Kobayashi et al.  
Serial No. : 10/551,866  
Filed : October 3, 2005  
Title : PHARMACEUTICAL AGENTS

Art Unit : 1641  
Examiner : Unknown

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL

The following correspondence relating to this application is enclosed for filing:

1. Information Disclosure Statement (1 page);
2. Form PTO-1449 (1 page);
3. Copies of cited references (16 references);
4. Copy of International Search Report (6 pages); and
5. A return postcard.

Please date stamp and return the enclosed postcard. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date:

June 13, 2006

M. Angela Parsons, Ph.D.  
Reg. No. 44,282

Fish & Richardson P.C.  
60 South Sixth Street, Suite 3300  
Minneapolis, MN 55402  
(612) 335-5070 telephone  
(612) 288-9696 facsimile

60362539.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


June 13, 2006

Date of Deposit

Signature

Lisa M. Becker

Typed or Printed Name of Person Signing Certificate



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Masanobu Kobayashi et al.  
Serial No. : 10/551,866  
Filed : October 3, 2005  
Title : PHARMACEUTICAL AGENTS

Art Unit : 1641  
Examiner : Unknown

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. §1.98(a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. A copy of a communication from a foreign patent office in a counterpart application is also enclosed. Please note that the reference Desig. ID No. AN is a Japanese document. Please refer to the enclosed International Search Report for an explanation of relevance.

This statement is being filed before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date:

June 13, 2006

M. Angela Parsons, Ph.D.

Reg. No. 44,282

Fish & Richardson P.C.  
60 South Sixth Street, Suite 3300  
Minneapolis, MN 55402  
Telephone: (612) 335-5070  
Facsimile: (612) 288-9696

60362292.doc

**CERTIFICATE OF MAILING BY FIRST CLASS MAIL**

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


June 13, 2006

Date of Deposit

Signature

Lisa M. Becker

Typed or Printed Name of Person Signing Certificate



|   |  |  |                                      |
|---|--|--|--------------------------------------|
| <b>Substitute Form PTO-1449</b><br>(Modified 12/1999)<br><b>Information Disclosure Statement<br/>by Applicant</b><br>(Use several sheets if necessary)<br><br>(37 CFR §1.98(b)) | <b>U.S. Department of Commerce<br/>Patent and Trademark Office</b> | <b>Attorney's Docket No.</b><br>18220-003US1 | <b>Application No.</b><br>10/551,866 |
|   | <b>Applicant</b><br>Masanobu Kobayashi et al.                      |  |                                      |
|   | <b>Filing Date</b><br>October 3, 2005                              | <b>Group Art Unit</b><br>1641                |                                      |

| U.S. Patent Documents |           |                 |                  |          |       |          |                            |
|-----------------------|-----------|-----------------|------------------|----------|-------|----------|----------------------------|
| Examiner Initial      | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
|                       | AA        |                 |                  |          |       |          |                            |

| Other Documents (include Author, Title, Date, and Place of Publication) |           |  |
|---|-----------|--|
| Examiner Initial  | Desig. ID | Document   |
|   | AB        | Brown, "Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies," <u>Mol. Med. Today</u> , 2000, 61:157-162  |
|   | AC        | Brown and Giaccia, "The Unique Physiology of Solid Tumors: Opportunities (and Problems) for Cancer Therapy," <u>Cancer Res.</u> , 1998, 58:1408-1416   |
|   | AD        | Comerford et al., "Hypoxia-inducible Factor-1-dependent Regulation of the Multidrug Resistance ( <i>MDR1</i> ) Gene," <u>Cancer Res.</u> , 2002, 62:3387-3394                                  |
|   | AE        | Cuyper et al., "Murine Leukemia Virus-Induced T-Cell Lymphomagenesis: Integration of Proviruses in a Distinct Chromosomal Region," <u>Cell</u> , 1984, 37:141-150                              |
|   | AF        | Dhanasekaran et al., "Delineation of prognostic biomarkers in prostate cancer," <u>Nature</u> , 2001, 412:822-826  |
|   | AG        | Luk et al., "Effect of Transient Hypoxia on Sensitivity to <b>Doxorubicin</b> in Human and Murine Cell Lines," <u>J. Natl. Cancer Inst.</u> , 1990, 82:684-692                                 |
|   | AH        | Möröy et al., "Expression of a <i>Pim-1</i> transgene accelerates lymphoproliferation and inhibits apoptosis in <i>lpr/lpr</i> mice," <u>Proc. Natl. Acad. Sci. USA</u> , 1993, 90:10734-10738 |
|   | AI        | Niizeki et al., "Hypoxia enhances the expression of autocrine motility factor and the motility of human pancreatic cancer cells," <u>Br. J. Cancer</u> , 2002, 86:1914-1919                    |
|   | AJ        | Sakata et al., "Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance," <u>Br. J. Cancer</u> , 1991, 64:809-814   |
|   | AK        | Sanna and Rofstad, "Hypoxia-Induced Resistance to Doxorubicin and Methotrexate in Human Melanoma Cell Lines <i>In Vitro</i> ," <u>Int. J. Cancer</u> , 1994, 58:258-262                        |
|   | AL        | Selten et al., "Proviral activation of the putative oncogene <i>Pim-1</i> in MuLV induced T-cell lymphomas," <u>EMBO J.</u> , 1985, 4(7):1793-1798   |
|   | AM        | Teh, "Pim-1 induced by hypoxia is involved in drug resistance and tumorigenesis of solid tumor cells," <u>Hokkaido Igaku Zasshi</u> , 2004, 79:19-23, 25-26                                    |
|   | AN        | Teicher, "Hypoxia and drug resistance," <u>Cancer Metastasis Rev.</u> , 1994, 13:139-168   |
|   | AO        | Verbeek et al., "Mice Bearing the <i>Eμ-myc</i> and <i>Eμ-pim-1</i> Transgenes Develop Pre-B-Cell Leukemia Prenatally," <u>Mol. Cell. Biol.</u> , 1991, 11(2):1176-1179                        |
|   | AP        | Wang et al., "Pim-1: A serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis," <u>J. Vet. Sci.</u> , 2001, 2(3):167-179                       |
|   | AQ        | Zakut-Houri et al., "The cDNA sequence and gene analysis of the human <i>pim</i> oncogene," <u>Gene</u> , 1987, 54:105-111   |

|  |                        |
|--|------------------------|
| <b>Examiner Signature</b>  | <b>Date Considered</b> |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                        |